Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

Bastian von Tresckow, Michelle Fanale, Kirit M. Ardeshna, Robert Chen, Julia Meissner, Franck Morschhauser, Craig Moskowitz, Pier Luigi Zinzani, Hilde Giezek, Arun Balakumaran, Thao T. Vo, Monika Raut, Pauline Brice

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were ≥90% at week 12 and ≥70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts. Clinicaltrials.gov identifier: NCT02453594.

Original languageEnglish (US)
Pages (from-to)2705-2711
Number of pages7
JournalLeukemia and Lymphoma
Volume60
Issue number11
DOIs
StatePublished - Sep 19 2019

Keywords

  • Classical Hodgkin lymphoma
  • KEYNOTE-087
  • health-related quality-of-life
  • patient-reported outcomes
  • pembrolizumab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma'. Together they form a unique fingerprint.

  • Cite this

    von Tresckow, B., Fanale, M., Ardeshna, K. M., Chen, R., Meissner, J., Morschhauser, F., Moskowitz, C., Zinzani, P. L., Giezek, H., Balakumaran, A., Vo, T. T., Raut, M., & Brice, P. (2019). Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. Leukemia and Lymphoma, 60(11), 2705-2711. https://doi.org/10.1080/10428194.2019.1602262